Controlled clinical trials in neurological disease
著者
書誌事項
Controlled clinical trials in neurological disease
(Foundations of neurology)
Kluwer Academic Publishers, c1990
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
The evaluation of the efficacy and safety of a clinical tool, be it a diagnostic technique, a preventive methodology, or a therapeutic intervention, is an im portant responsibility of physicians. The history of medicine is characterized by the authoritarianisms of teachers and of organizations giving way to the clinical experience of physicians; authoritarian dictum was replaced by case report and then by case series. As physicians learned to substitute the analysis of data for the inconsistencies of dictums and anecdotes, the problems of the case series as an investigative tool became more evident: patient selection criteria, measurements of outcome, significance of results, and extrapolation of conclusions to the community of patients. In response to these issues, the methodology of the controlled clinical trial has evolved and with it the instru ments of study design and of biostatistics as aids to study design and data analysis. The medical - surgical armamentarium has evolved from being dependent solely upon the observations and conclusions of a skilled clinician to being constructed upon the systematic collection and evaluation of data by a team of skilled clinicians and their statistical colleagues: this is the controlled clinical trial. During the past two decades, the evaluation of clinical approaches to pre vention and therapy has become particularly important to clinicians concerned with nervous system dysfunction. There has been and continues to be an explosion of information from the basic neurosciences and from the applica tion of biotechnology to the nervous system.
目次
I. Design of Controlled Clinical Trials.- 1. Clinical considerations.- 2. Initial statistical considerations.- 3. Statistical and epidemiological considerations.- II. Implementation and Interpretations of Controlled Clinical Trials (Example: Epilepsy).- 4. Perspective of the patient.- 5. Perspective of the participating investigator.- 6. Perspective of the clinical center.- 7. Perspective of the coordinating center.- 8. Perspective of the food and drug administration.- 9. Perspective of the pharmaceutical industry.- 10. Perspective of the insurance industry.- III. Applications of Controlled Clinical Trials to Diseases of the Nervous System.- 11. Cerebrovascular disease.- 12. Epilepsy.- 13. Movement disorders.- 14. Head and spinal cord injury.- 15. Headache.- 16. Peripheral neuropathy.- 17. Guillain-Barre: Plasmapheresis.- 18. Motor neuron disease.- 19. Myasthenia gravis.- 20. Muscular dystrophy.- 21. Multiple sclerosis.- 22. Brain tumors.- 23. Alzheimer's disease.- 24. Viral diseases: Herpes simplex encephalitis.- 25. Parasitic diseases.
「Nielsen BookData」 より